Health Canada inks Abbott deal

LIBERTYVILLE TOWNSHIP - Abbott Laboratories announced Monday that it has received approval from Health Canada to produce the XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. Libertyville Township-based Abbott will launch XIENCE V in Canada immediately, according to the company. The coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug everolimus in a controlled manner over time to help prevent the artery from becoming blocked again following the stent procedure.